Home >Research Discovery>Discovery Biology
Introduction of group leader
Office phone: +82-31-8018-8180
Office location: R4.25-2
My laboratory is interested in applied molecular virology of hepatitis B and C viruses (HBV & HCV). Research tools and assays were developed supporting HTS campaigns and mechanism of action (MoA) studies. With the infectious HCV cell culture system, more than 250,000 compounds were screened, viral RNA replication inhibitors excluded and HCV E1/E2 entry inhibitor included. Thereby, antivirals have been identified acting on viral entry and secretion. Surprisingly, one compound series exclusively inhibits HCV genotype 2; mapping of the genotype determining region and MoA studies are ongoing. Another compound series, which inhibits major HCV genotypes, is currently being characterized and a lead optimization program is being pursued, which is financially supported by the Korea Drug Development Fund (KDDF). To date, state-of-the-art HCV therapies cost more than USD 100,000; this high economic burden will limit access to therapies. Consequently, we are looking into affordable alternatives, e.g. screening and characterization of natural compounds, and we seek non-profit organizations to jointly develop drugs for patient in needs.
We are also on a quest to identify and characterize drugs with a novel MoA, which potentially could cure chronic hepatitis B. In collaboration with a local lab and an international pharmaceutical company, we screened for pre-genomic RNA encapsidation inhibitors and for immunomodulator restoring innate immunity in chronically HBV infected hepatocytes. Furthermore, in collaboration with a German lab, we developed a robust infectious HBV cell culture system in 384-well plates suitable for HTS. With this cutting-edge technology, small molecule compound libraries will be screened to identify and characterize inhibitors targeting HBV entry, capsid disassembly/trafficking, cccDNA synthesis, etc.
With the re-emergence of the Ebola virus in Africa and the quick spread to other countries, this pathogen has been recognized as a global threat. In order to tackle Ebola, we devised strategies to identify immunomodulator, replication and entry inhibitors. Currently, we are looking for external collaboration partners to develop HTS assays and to characterize identified hit compounds.
A new high-content screening assay of the entire hepatitis B virus life cycle identifies novel antivirals
Jaewon Yang, Alexander Konig, Soonju Park, Eunji Jo, Pil Soo Sung, Seung Kew Yoon, Eva Zusinaite, Denis Kainov, David Shum, Marc Peter Windisch
J Hepatol Rep. 2021 Apr 30;3(4):100296
Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor
Eunji Jo, Dong-Kyun Ryu, Alexander König, Soonju Park, Yoojin Cho, Sang-Hyun Park, Tae-Hee Kim, Seung Kew Yoon, Wang-Shick Ryu, Jonathan Cechetto, Marc P Windisch
Antiviral Res. 2020 Mar;175:104709
High tolerance of hepatitis B virus to thermal disinfection
Alexander König, Thoa Thi Than, Daniel Todt, Seung Kew Yoon, Jochen Steinmann, Eike Steinmann, Marc P Windisch
J Hepatol. 2019 Dec;71(6):1249-1251
Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells
Alexander König, Jaewon Yang, Eunji Jo, Kyu Ho Paul Park, Hyun Kim, Thoa Thi Than, Xiyong Song, Xiaoxuan Qi, Xinghong Dai, Soonju Park, David Shum, Wang-Shick Ryu, Jung-Hee Kim, Seung Kew Yoon, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, Wolfram Hubert Gerlich, Marc P Windisch
J Hepatol. 2019 Aug;71(2):289-300
High Environmental Stability of Hepatitis B Virus and Inactivation Requirements for Chemical Biocides
Thoa Thi Than, Eunji Jo, Daniel Todt, Phuong Hong Nguyen, Jochen Steinmann, Eike Steinmann, Marc P Windisch
J Infect Dis. 2019 Mar 15;219(7):1044-1048